Karen D. Barton

Karen D. Barton

Auto-generated profile, based on publicly available information

Karen D. Barton

Duke University Medical Center Library & Archives, Duke University School of Medicine , Durham, North Carolina

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Journal of Clinical Anesthesia
Verified
Journal Article
Closed access
HTHon Sen Tan
Hon Sen Tan
CTCameron Taylor
Cameron Taylor
DWDan Weikel
Dan Weikel
KBKaren Barton
Karen Barton
AHAshraf S. Habib
Ashraf S. Habib

19 August 2020 in Transfusion
Verified
Journal Article
Closed access
PDF file
COChinonso Onuoha
Chinonso Onuoha
KBKaren D. Barton
Karen D. Barton
EWEdward C.C. Wong
Edward C.C. Wong
JRJay S. Raval
Jay S. Raval
MRMarian A. Rollins‐Raval
Marian A. Rollins‐Raval
OOOluwatoyosi A. Onwuemene
Oluwatoyosi A. Onwuemene

21 July 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
HSHannah-Lise T. Schofield
Hannah-Lise T. Schofield
VFVanessa A. Fabrizio
Vanessa A. Fabrizio
SBSuzanne Braniecki
Suzanne Braniecki
WPWendy Pelletier
Wendy Pelletier
HEHesham Eissa
Hesham Eissa
KPKristin M. Page
Kristin M. Page

19 July 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
JPJens Emil Vang Petersen
Jens Emil Vang Petersen
TKThomas Kallemose
Thomas Kallemose
KBKaren D Barton
Karen D Barton
ACAvshalom Caspi
Avshalom Caspi
LRLine Jee Hartmann Rasmussen
Line Jee Hartmann Rasmussen
Introduction Chronic inflammation is increasingly recognised as a major contributor to disease, disability and ultimately death, but measuring the levels of chronic inflammation remains non-canonised, making it difficult to relate chronic inflammation and mortality. Soluble urokinase plasminogen activator receptor (suPAR), an emerging biomarker of chronic inflammation, has been proposed as a prognostic biomarker associated with future incidence of chronic disease and mortality in general as well as patient populations. Proper prognostic biomarkers are important as they can help improve risk stratification in clinical settings and provide guidance in treatment or lifestyle decisions as well as in the design of randomised trials. Here, we wish to summarise the evidence about the overall association of the biomarker suPAR with mortality in healthy, general and patient populations across diseases. Methods and analysis The search will be conducted using Medline, Embase and Scopus databases from their inception to 03 June 2020 to identify studies investigating ‘suPAR’ and ‘mortality’. Observational studies and control groups from intervention studies written in English or Danish will be included. The ‘Quality In Prognosis Studies’ tool will be used to assess the risk of bias for the studies included. Unadjusted and adjusted mortality outcome measures (eg, risk ratios, ORs, HRs) with 95% CIs will be extracted for healthy individuals, general and patient populations. The primary outcome is all-cause mortality within any given follow-up. Subgroup analyses will be performed based on time of outcome, cause of death, population type, adjustments for conventional risk factors and inflammation markers. Ethics and dissemination This systematic review will synthesise evidence on the use of suPAR as a prognostic marker for mortality. The results will be disseminated by publication in a peer-reviewed journal. Data used will be obtained from published studies, and ethics approval is therefore not necessary for this systematic review. Trial registration number PROSPERO CRD42020167401.

6 August 2025 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
KSKatherine N Sutton
Katherine N Sutton
ELEmily Lydon
Emily Lydon
ARAbigail Rader
Abigail Rader
KBKaren D Barton
Karen D Barton
LSLesley A Skalla
Lesley A Skalla
HKHeather A King
Heather A King
Background: Acute bacterial skin and skin structure infections (ABSSSIs) can diminish patients’ health-related quality of life (HRQoL). We performed a systematic review to determine how HRQoL has been measured in patients with ABSSSIs. Methods: We searched MEDLINE (PubMed), Embase (Elsevier), and CINAHL (EBSCO) for articles published between database inception and 14 October 2022, following a prospectively registered protocol in PROSPERO (CRD42021225414). Results: We identified 37 articles that employed 42 distinct measures: 26 generic measures assessing HRQoL; 14 condition-specific measures, including repurposed dermatologic or surgical HRQoL measures; and 2 author-developed questionnaires assessing treatment-related HRQoL. We found reduced HRQoL for patients experiencing ABSSSIs, which usually exhibited rapid onset and resolution. Pain had the greatest negative impact on HRQoL, and the most common HRQoL domain impacted was physical functioning. Conclusions: Progress has been made in the development and use of HRQoL measures, yet we did not identify a repurposed or novel tool that best captures HRQoL in patients with ABSSSI.

2 January 2018 in Medical Reference Services Quarterly
Verified
Journal Article
Closed access
JFJonquil D. Feldman
Jonquil D. Feldman
ELEmme Lopez
Emme Lopez
CGChristine S. Gaspard
Christine S. Gaspard
KBKaren D. Barton
Karen D. Barton
LBLuis F. Barcenes
Luis F. Barcenes
At an academic health science center, librarians identified problems, weaknesses, and strengths in reference services. The on-call reference schedule was discontinued and a question flowchart was developed for circulation staff. Only research questions were referred to librarians, who would respond if available. Circulation staff perceived the unscheduled, voluntary model was not working well for the patrons or the staff. After two months, the schedule was reinstated with a hybrid version of the previous on-call format. In the process of changing the service model, the library staff also underwent a cultural change.